Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

Key Points

  • Bristol Myers Squibb plans to cut $2 billion in costs by 2027 to fund new drug development and growth.
  • The company issued 2025 revenue guidance below Wall Street expectations due to competition from generics.
  • Fourth-quarter results exceeded expectations, driven by strong sales of Eliquis and the growth portfolio.

Summary

Bristol Myers Squibb announced a significant cost-cutting initiative, aiming to reduce expenses by $2 billion by the end of 2027. This move is part of a broader strategy to reinvest in new science and drug brands to foster long-term growth. The company has already planned to save $1.5 billion by 2025, with the latest announcement expanding on these efforts. The cost savings are intended to offset the anticipated revenue loss from key drugs like Eliquis and Opdivo, which are expected to lose market exclusivity soon. Despite issuing a 2025 revenue guidance that fell short of Wall Street's expectations, Bristol Myers Squibb's fourth-quarter performance was robust, surpassing forecasts with an 8% revenue increase to $12.34 billion, largely due to strong sales of Eliquis and its growth portfolio. However, the company faces challenges from generic competition and potential price negotiations under the Inflation Reduction Act, which could impact future sales of several cancer treatments.

cnbc
February 6, 2025
Stocks
Read article

Related news